“Positive study results and a successful capital raise provide a stable foundation for the future, where the focus will be on the regulatory work ahead of the market launch. BioStock contacted Neola Medical’s CEO Hanna Sjöström to find out more about her view of the third quarter and what she sees ahead of her for 2023.”

Don’t miss BioStock’s new article about Neola Medical and the third quarter 2022, where the significant events are highlighted and CEO Hanna Sjöström comments the company’s development and upcoming work.

Read the entire article here: BioStock – Regulatory focus for Neola Medical

Q3-report 2022 is available here: Neola Medical – Reports and Financial calendar